Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

HIV Patient Advocates Want Facial-Filler Option, Irrespective Of Depression

This article was originally published in The Gray Sheet

Executive Summary

Psychologists, social workers and patient advocates are applauding a CMS proposal to cover dermal filler treatments for HIV patients with symptoms of facial wasting, a common side effect of medical treatment

You may also be interested in...



Facial Filler Coverage Will Help Boost Quality Of Life For HIV Patients - CMS

In a March 23 decision memo, CMS says it will now cover dermal injections to treat facial lipodystrophy when the stigmatizing side effect of antiretroviral HIV drugs is a significant contributor to a Medicare beneficiary's depression

Facial Filler Coverage Will Help Boost Quality Of Life For HIV Patients - CMS

In a March 23 decision memo, CMS says it will now cover dermal injections to treat facial lipodystrophy when the stigmatizing side effect of antiretroviral HIV drugs is a significant contributor to a Medicare beneficiary's depression

Medicare In Brief

Facial-filler coverage proposal: CMS is taking comments through Jan. 22 on its proposal to cover dermal injections for facial lipodystrophy syndrome only in HIV patients who are depressed because of the physical signs of HIV treatment. Under the proposal, all other indications would be nationally non-covered, the agency said, because "we did not find evidence of improvement in any other health outcomes." The coverage analysis focuses on two synthetic injectable products for treating HIV facial lipoatrophy: poly-L-lactic acid (Sculptra from Sanofi Aventis) and calcium hydroxylapatite (Radiesse from BioForm Medical). Currently coverage decisions for the treatment, which helps fill areas of fat lost in a patient's cheeks due to some HIV drug therapies, are left to local contractors. The Medicare agency opened the coverage analysis last July (1"The Gray Sheet" July 20, 2009), following a benefits category analysis opened last January (2"The Gray Sheet" Jan. 26, 2009). CMS plans a final decision by March 23

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT028439

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel